JPWO2019148161A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019148161A5 JPWO2019148161A5 JP2020562086A JP2020562086A JPWO2019148161A5 JP WO2019148161 A5 JPWO2019148161 A5 JP WO2019148161A5 JP 2020562086 A JP2020562086 A JP 2020562086A JP 2020562086 A JP2020562086 A JP 2020562086A JP WO2019148161 A5 JPWO2019148161 A5 JP WO2019148161A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- pharmaceutically acceptable
- cycloalkyl
- acceptable salt
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862623516P | 2018-01-29 | 2018-01-29 | |
| US62/623,516 | 2018-01-29 | ||
| PCT/US2019/015547 WO2019148161A1 (en) | 2018-01-29 | 2019-01-29 | 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021512161A JP2021512161A (ja) | 2021-05-13 |
| JPWO2019148161A5 true JPWO2019148161A5 (https=) | 2022-01-17 |
| JP2021512161A5 JP2021512161A5 (https=) | 2022-01-17 |
| JP7337395B2 JP7337395B2 (ja) | 2023-09-04 |
Family
ID=67394794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020562086A Active JP7337395B2 (ja) | 2018-01-29 | 2019-01-29 | Ｃｄｋ４およびｃｄｋ６阻害剤としての２ｈ－インダゾール誘導体およびその治療上の使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11352341B2 (https=) |
| EP (1) | EP3746072B1 (https=) |
| JP (1) | JP7337395B2 (https=) |
| KR (1) | KR20200115583A (https=) |
| CN (1) | CN111989099A (https=) |
| AU (1) | AU2019211491B2 (https=) |
| BR (1) | BR112020015405A2 (https=) |
| CA (1) | CA3088381A1 (https=) |
| EA (1) | EA202091450A1 (https=) |
| IL (1) | IL275948A (https=) |
| MX (1) | MX2020007959A (https=) |
| PH (1) | PH12020551155A1 (https=) |
| SG (1) | SG11202006748RA (https=) |
| TW (1) | TW201940166A (https=) |
| WO (1) | WO2019148161A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019018584A1 (en) | 2017-07-18 | 2019-01-24 | GiraFpharma LLC | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS |
| EP3654982A4 (en) | 2017-07-18 | 2021-04-14 | Nuvation Bio Inc. | 1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES |
| WO2019161224A1 (en) | 2018-02-15 | 2019-08-22 | GiraFpharma LLC | Heterocyclic compounds as kinase inhibitors |
| PL3806898T3 (pl) * | 2018-06-18 | 2026-02-23 | UCB Biopharma SRL | Antagonista gremlin-1 do zastosowania w leczeniu nowotworu |
| EP3911324A4 (en) | 2019-01-18 | 2022-08-17 | Nuvation Bio Inc. | 1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES |
| EP3911323A4 (en) | 2019-01-18 | 2022-11-16 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS |
| AU2020215684B2 (en) * | 2019-01-29 | 2025-08-21 | Beta Pharma, Inc. | 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases |
| MX2021013531A (es) | 2019-05-05 | 2022-02-11 | Qilu Regor Therapeutics Inc | Inhibidores de cdk. |
| EP4159728A4 (en) * | 2020-06-22 | 2024-06-26 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | MANUFACTURING PROCESS FOR CDK4/6 INHIBITOR |
| US20230416271A1 (en) * | 2020-11-26 | 2023-12-28 | Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. | Heteroarylquinazoline compounds as protein kinase inhibitors |
| WO2022113003A1 (en) | 2020-11-27 | 2022-06-02 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2251677T3 (es) | 2002-01-22 | 2006-05-01 | Warner-Lambert Company Llc | 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas. |
| ATE412650T1 (de) | 2003-07-11 | 2008-11-15 | Warner Lambert Co | Isethionat salz eines selektiven cdk4 inhibitors |
| CN1956982A (zh) | 2004-05-21 | 2007-05-02 | 万有制药株式会社 | 具有氨基噻唑骨架的Cdk4、6选择性抑制剂 |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| US9259399B2 (en) | 2007-11-07 | 2016-02-16 | Cornell University | Targeting CDK4 and CDK6 in cancer therapy |
| ES2522346T3 (es) | 2008-08-22 | 2014-11-14 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de CDK |
| JO2885B1 (en) | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
| US9796701B2 (en) | 2013-12-31 | 2017-10-24 | Xuanzhu Pharma Co., Ltd. | Kinase inhibitor and use thereof |
| MY187555A (en) | 2014-07-24 | 2021-09-29 | Beta Pharma Inc | 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof |
| US9969719B2 (en) | 2015-03-11 | 2018-05-15 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug |
| CN107286134B (zh) | 2016-04-11 | 2019-04-12 | 上海勋和医药科技有限公司 | 2，4-二取代嘧啶衍生物作为cdk抑制剂及其应用 |
-
2019
- 2019-01-29 CA CA3088381A patent/CA3088381A1/en not_active Abandoned
- 2019-01-29 BR BR112020015405-9A patent/BR112020015405A2/pt not_active Application Discontinuation
- 2019-01-29 EA EA202091450A patent/EA202091450A1/ru unknown
- 2019-01-29 KR KR1020207024587A patent/KR20200115583A/ko not_active Withdrawn
- 2019-01-29 JP JP2020562086A patent/JP7337395B2/ja active Active
- 2019-01-29 CN CN201980010752.7A patent/CN111989099A/zh active Pending
- 2019-01-29 TW TW108103389A patent/TW201940166A/zh unknown
- 2019-01-29 MX MX2020007959A patent/MX2020007959A/es unknown
- 2019-01-29 SG SG11202006748RA patent/SG11202006748RA/en unknown
- 2019-01-29 EP EP19743187.7A patent/EP3746072B1/en active Active
- 2019-01-29 US US16/965,376 patent/US11352341B2/en active Active
- 2019-01-29 WO PCT/US2019/015547 patent/WO2019148161A1/en not_active Ceased
- 2019-01-29 AU AU2019211491A patent/AU2019211491B2/en active Active
-
2020
- 2020-07-09 IL IL275948A patent/IL275948A/en unknown
- 2020-07-29 PH PH12020551155A patent/PH12020551155A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512161A5 (https=) | ||
| JPWO2019148161A5 (https=) | ||
| CN115803326A (zh) | Egfr抑制剂及其制备方法与在药学上的应用 | |
| JP4593929B2 (ja) | キノリン及びイソキノリン誘導体類、それらの生成方法及び炎症インヒビターとしてのそれらの使用 | |
| CN115803325A (zh) | 一种egfr抑制剂及其制备方法和应用 | |
| JP2020500862A5 (https=) | ||
| JP2021519783A5 (https=) | ||
| JPWO2019212990A5 (https=) | ||
| JP5901634B2 (ja) | キナゾリン化合物及びその使用方法 | |
| JP2018517686A5 (https=) | ||
| CN110582483A (zh) | 含邻氨基杂芳环炔基的化合物及其制备方法和用途 | |
| JP2006523216A5 (https=) | ||
| JP2017519754A5 (https=) | ||
| CN102395576A (zh) | 调控jak激酶的喹唑啉衍生物和其使用方法 | |
| JP2005516067A5 (https=) | ||
| CN106660974A (zh) | 含氨磺酰基的1,2,5‑噁二唑类衍生物、其制备方法及其在医药上的应用 | |
| JP2019528307A5 (https=) | ||
| RU2018129344A (ru) | Производное хиназолинона, способ его получения, фармацевтическая композиция и применения | |
| CN116113416A (zh) | 四环类衍生物、其制备方法和其医药上的用途 | |
| JP2013537171A (ja) | 複素環アミノベルバミン誘導体、その調製方法及び使用 | |
| CN117062819A (zh) | 多环化合物及其用途 | |
| JPWO2022182857A5 (https=) | ||
| JP2013544794A5 (https=) | ||
| JP2024125139A5 (https=) | ||
| JPWO2021076691A5 (https=) |